News articles about Theravance Biopharma (NASDAQ:TBPH) have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Theravance Biopharma earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.1683472880426 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the headlines that may have impacted Accern’s rankings:
- Theravance Biopharma, Inc. (TBPH) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- Cantor Fitzgerald Analysts Give Theravance Biopharma Inc (TBPH) a $55.00 Price Target (americanbankingnews.com)
- Theravance Biopharma Inc (TBPH) Research Coverage Started at Evercore ISI (americanbankingnews.com)
- Zacks: Analysts Expect Theravance Biopharma, Inc. (NASDAQ:TBPH) Will Announce Quarterly Sales of $3.59 Million (americanbankingnews.com)
- See what the IHS Markit Score report has to say about Theravance Biopharma Inc. (finance.yahoo.com)
Shares of Theravance Biopharma (NASDAQ:TBPH) opened at 27.40 on Friday. The stock’s market cap is $1.47 billion. The stock has a 50 day moving average price of $33.89 and a 200 day moving average price of $35.36. Theravance Biopharma has a 12 month low of $23.15 and a 12 month high of $43.44.
Several brokerages have weighed in on TBPH. Evercore ISI initiated coverage on Theravance Biopharma in a research note on Wednesday. They issued an “outperform” rating and a $45.00 target price on the stock. BidaskClub downgraded Theravance Biopharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Cantor Fitzgerald set a $55.00 target price on Theravance Biopharma and gave the stock a “buy” rating in a research report on Wednesday, July 19th. Needham & Company LLC boosted their target price on Theravance Biopharma from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, May 11th. Finally, Leerink Swann set a $47.00 price target on Theravance Biopharma and gave the stock a “buy” rating in a report on Wednesday, May 10th. Four investment analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $41.63.
COPYRIGHT VIOLATION WARNING: “Theravance Biopharma (NASDAQ:TBPH) Earns Daily Media Sentiment Rating of 0.20” was published by BNB Daily and is owned by of BNB Daily. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/theravance-biopharma-nasdaqtbph-receiving-somewhat-favorable-news-coverage-study-shows-updated-updated.html.
In other news, Director Henrietta Fore bought 6,000 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was acquired at an average price of $23.99 per share, with a total value of $143,940.00. Following the completion of the purchase, the director now directly owns 24,000 shares of the company’s stock, valued at $575,760. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Rick E. Winningham purchased 10,000 shares of Theravance Biopharma stock in a transaction on Friday, August 11th. The stock was bought at an average price of $24.50 per share, with a total value of $245,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 866,377 shares of the company’s stock, valued at approximately $21,226,236.50. The disclosure for this purchase can be found here. Company insiders own 6.10% of the company’s stock.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.